Age is just a number, the wrong number

Affiliations

Editorial

Susan Bal et al. Cancer. 2020.

. 2020 Dec 1;126(23):5014-5016.

doi: 10.1002/cncr.33170. Epub 2020 Sep 23.

¹ Division of Hematology and Oncology, Department of Medicine, University of Alabama at Birmingham, Birmingham, Alabama.

No abstract available

Keywords: age; autologous hematopoietic cell transplantation; frailty; multiple myeloma; toxicity.

Comment on

Age no bar: A CIBMTR analysis of elderly patients undergoing autologous hematopoietic cell transplantation for multiple myeloma.
Munshi PN, Vesole D, Jurczyszyn A, Zaucha JM, St Martin A, Davila O, Agrawal V, Badawy SM, Battiwalla M, Chhabra S, Copelan E, Kharfan-Dabaja MA, Farhadfar N, Ganguly S, Hashmi S, Krem MM, Lazarus HM, Malek E, Meehan K, Murthy HS, Nishihori T, Olin RL, Olsson RF, Schriber J, Seo S, Shah G, Solh M, Tay J, Kumar S, Qazilbash MH, Shah N, Hari PN, D'Souza A. Munshi PN, et al. Cancer. 2020 Dec 1;126(23):5077-5087. doi: 10.1002/cncr.33171. Epub 2020 Sep 23. Cancer. 2020. PMID: 32965680 Free PMC article.

1. Munshi PN, Vesole D, Jurczyszyn A, et al. Age no bar: a CIBMTR analysis of elderly patients undergoing autologous hematopoietic stem cell transplantation for multiple myeloma. Cancer. 2020;126.
1. Badros A, Barlogie B, Siegel E, et al. Autologous stem cell transplantation in elderly multiple myeloma patients over the age of 70 years. Br J Haematol. 2001;114:600-607.
1. Kumar SK, Dingli D, Lacy MQ, et al. Autologous stem cell transplantation in patients of 70 years and older with multiple myeloma: results from a matched pair analysis. Am J Hematol. 2008;83:614-617.
1. Palumbo A, Bringhen S, Petrucci MT, et al. Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. Blood. 2004;104:3052-3057.
1. Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial. Lancet. 2007;370:1209-1218.